Uricase from Candida sp.
SIGMA/U0880 - recombinant, expressed in E. coli, lyophilized powder, ≥2 units/mg solid
Synonym: Urate: oxygen oxoreductase
CAS Number: 9002-12-4
MDL Number: MFCD00082126
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: U0880-1000UN
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: U0880-250UN
| form | lyophilized powder |
| InChI | 1S/C18H23N4O14P.H3N/c23-5 |
| InChI key | VPXDHZMLJOJKOX-UHFFFAOYSA |
| mol wt | 35 kDa by SDS-PAGE |
| Quality Level | 200  |
| recombinant | expressed in E. coli |
| specific activity | ≥2 units/mg solid |
| storage temp. | −20°C |
| Application: | Uricase from Candida sp. has been used: • to eliminate urate in plasma samples and evaluate the contribution of urate to the total plasma antioxidant capacity • to intraperitoneally inject the mice to study the role of uric acid in fibrin extracellular traps (ET) formation • for elimination of uric acid in ferric reducing/antioxidative power (FRAP) assay to measure the total antioxidative capacity of human plasma sample; in uricase-based biosensors |
| Biochem/physiol Actions: | Uricase participates in purine catabolism. It catalyzes the conversion of highly insoluble uric acid into 5-hydroxyisourate. Accumulation of uric acid causes liver/kidney damage or chronically causes gout. In mice, a mutation in the gene encoding uricase causes a sudden increase in uric acid. Mice, deficient in this gene, exhibit hyperuricemia, hyperuricosuria, and uric acid crystalline obstructive nephropathy. |
| General description: | Uricase deficient mice develop uric acid nephropathy and diabetes insipidus which can be mitigated with recombinant uricase treatment. |
| General description: | Uricase is a homo-tetrameric protein with its active sites at the head-to-tail monomer-dimer interface. |
| Packaging: | 250, 1000 units in glass bottle |
| Physical form: | Powder; contains citrate and sucrose |
| Unit Definition: | One unit will oxidize 1.0 μmole of uric acid to allantoin per minute at pH 8.5 at 25 °C. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| activity | specific activity: ≥2 units/mg solid |
| Storage Temp. | −20°C |
| Enzyme Commission (EC) Number | 1.7.3.3 ( BRENDA  | IUBMB ) |
| UNSPSC | 12352204 |